Oxonica is a publicly traded international nanotechnology company with subdivisions in energy, healthcare, materials, and security. Oxonica was founded in 1998 by Prof. Peter Dobson and Dr. Gareth Wakefield out of the Universit of Oxford. The company was founded around a core set of patents e
ncompassing nanoparticles and coatings that Oxonica sought to use in diagnostics, fuel additives, metal coatings, and topical treatments. Oxonica has U.S. offices in Mountain View, CA for its healthcare and security divisions and reported a gross profit of £6M from £10.3M revenue in 2006.www.Oxonica.com
Products
Oxonica's commercialized products are Envirox™ and Optisol™ from the energy and materials divisions, respectively, and the Nanoplex™ system is currently under development in the healthcare division.
Envirox™- A fuel born catalyst designed as an additive in diesel engines to reduce fuel consumption and emission. Technologically, Envirox™ is engineered from cerium oxide to make it active enough to be added at 5 mg/L of diesel. The catalyst acts by lowering the combustion temperature of carbon in the combustion chamber and improving the oxidation of unburnt fuel and carbon deposits. Refer to this pdf for more info.
Optisol™- A UV absorber used as an additive in sun-care and anti-aging products. Optisol™ is produced by incorporating manganese ions in the the major titanium dioxide component of the product. This provides a major competitive advantage, as the manganese ions cause Optisol™ to absorb free radicals and prevent them from harming the body.
Nanoplex™- Oxonica's acquisition of Nanoplex, Inc. in 2006 provided the company with Nanoplex™ system, which is a cost effective system capable of performing high throughput detection of multiple particles within human samples. The system uses gold nanoparticles, which are coated with Raman-activated dye and SiO2, and conjugated with antibodies that recognize targets within a tissue or blood sample. Through a process called Raman Scattering, the targets can be detected in stereotypical readouts that are analyzed by the physician. The major advantage of this system is its speed (under 30 min) and its ability to detect multiple targets in a single sample.
News
12.13.2007- Oxonica's security division completes technological milestones, prompting the business to receive $275K in follow-on orders from a total of $1.16M promised upon further completion of milestones.
9.27.2007- Oxonica signs a follow-on R&D agreement with Becton Dickinson, a major pharma company interested in the Nanoplex™ system. Under the terms of the agreement, BD will fund the development of Nanoplex™ to evaluate its use in clinical situations.
10.19.2006- Oxonica is named by Lux Research to be one of four nanotechnology startups of the greatest value to corporate partners.
7.6.2006- Oxonica's platform detection technology wins Nanotech Briefs Nano 50 Award.
(FIGURE from Nanotech-now.com)
3 comments:
welcome back!!! Where were you? I look forward to more commentary on the industry per se
Nice post there is as nanotech products like antimony tin oxide powder and carbon nanotubes are very useful products for the industries.
Post a Comment